{"nctId":"NCT00522041","briefTitle":"A Study to Determine the Effect of Nitroglycerin Ointment 0.4% (Cellegesic) on the Pain Associated With Chronic Anal Fissures","startDateStruct":{"date":"2007-08"},"conditions":["Fissure in Ano","Pain"],"count":248,"armGroups":[{"label":"Cellegesic (nitroglycerin 0.4%)","type":"EXPERIMENTAL","interventionNames":["Drug: Cellegesic"]},{"label":"Placebo 375 mg","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Cellegesic","otherNames":["0.4% nitroglycerin ointment","Rectogesic"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Consenting patients of either sex.\n* Between 18 and 75 years of age.\n* With a single, chronic, posterior midline anal fissure.\n* Defined as having anal pain for the 6 weeks prior to Screening.\n\nExclusion Criteria:\n\n* More than one anal fissure.\n* A fistula-in-ano or anal abscess.\n* Inflammatory bowel disease.\n* Fibrotic anal stenosis.\n* Anal fissure secondary to an underlying condition.\n* Any anal surgery.\n* Concomitant medication that may interfere with study evaluation.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Pain Intensity at Days 14-18","description":"Participants rated the pain associated with their chronic anal fissure over the preceding 24 hours on a 100 mm visual analog scale at Baseline and on Days 14 through 18. The average pain rating on Days 14 through 18 was calculated and used to determine the change from Baseline. The left-end of the visual analog scale was labelled \"least possible pain\" and the right-end of the visual analog scale was labelled \"worst possible pain\". The pain rating ranged from 0 to 100, with a higher score indicating more pain. A negative change score indicated improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.4","spread":"3.12"},{"groupId":"OG001","value":"-34.9","spread":"3.04"}]}]}]},{"type":"SECONDARY","title":"Time to an Improvement in Pain Intensity","description":"Participants rated the pain associated with their chronic anal fissure over the preceding 24 hours on a 100 mm visual analog scale (VAS) at Baseline and on each of the 21 treatment days of the study. The left-end of the visual analog scale was labelled \"least possible pain\" and the right-end of the visual analog scale was labelled \"worst possible pain\". The pain rating ranged from 0 to 100, with a higher score indicating more pain. Improvement was defined as either a ≥ 50% decrease or a ≥ 10 mm decrease from Baseline in rated pain intensity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":"0.6"},{"groupId":"OG001","value":"13.2","spread":"0.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"0.5"},{"groupId":"OG001","value":"7.2","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders","description":"Participants rated the pain associated with their chronic anal fissure over the preceding 24 hours on a 100 mm visual analog scale at Baseline and on Days 14 through 18. The average pain rating on Days 14 through 18 was calculated. The left-end of the visual analog scale was labelled \"least possible pain\" and the right-end of the visual analog scale was labelled \"worst possible pain\". The pain rating ranged from 0 to 100, with a higher score indicating more pain. A responder was defined as a participant with either a ≥ 50% decrease or a ≥ 10 mm decrease from Baseline in the 24 hour average pain intensity averaged over Days 14 to 18.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.4","spread":null},{"groupId":"OG001","value":"64.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.6","spread":null},{"groupId":"OG001","value":"85.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":123},"commonTop":["Headache","Dizziness","Diarrhoea","Nausea","Sinusitis"]}}}